Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
The integration of additional biomarker assessments into MTB workflows enhances precision oncology by expanding the pool of patients eligible for targeted therapies.
Authors
- W Dietmaier
- Daniel Heudobler (ORCID: https://orcid.org/0000-0002-8790-4584)
- Anja Troeger
- Anja M. Sedlmeier (ORCID: https://orcid.org/0000-0002-7564-3065)
- Hauke Christian Tews (ORCID: https://orcid.org/0009-0001-1068-2151)
- Felix Steger (ORCID: https://orcid.org/0000-0002-0762-2975)
- Marco J. Schnabel (ORCID: https://orcid.org/0000-0002-1535-2952)
- Elisabeth Bumes (ORCID: https://orcid.org/0000-0001-6915-3206)
- Kristina Wohlfart
- Konstantin Drexler (ORCID: https://orcid.org/0009-0004-6601-6299)
- B. Zwicker
- Florian Lüke (ORCID: https://orcid.org/0000-0001-5252-287X)
- Daniela Hirsch (ORCID: https://orcid.org/0000-0001-8883-922X)
- Till Kaltofen (ORCID: https://orcid.org/0000-0003-1137-211X)
- S. Haferkamp
- Alexander Immel (ORCID: https://orcid.org/0000-0002-8970-4383)
- Sabine Einhell
- Kirsten Utpatel (ORCID: https://orcid.org/0000-0001-8615-9677)
- Julia Maurer (ORCID: https://orcid.org/0009-0006-5340-2793)
- Ulrich Kaiser (ORCID: https://orcid.org/0000-0003-0321-5245)
- Christina Brummer (ORCID: https://orcid.org/0009-0002-6035-2916)
- Frederik Hierl
- Tobias Pukrop (ORCID: https://orcid.org/0000-0001-8781-8187)
- Diego F. Calvisi (ORCID: https://orcid.org/0000-0002-6038-8567)
- Sophie Schlosser-Hupf
- Matthias Grube
- Davor Lessel
- S. A. Klemm
- Stephan Seitz
- Ramona Erber
- Arne Kandulski
- Felix Keil
- Markus Perl
- Elena Lüftl
- Tom Schneider
- Alexander Scheiter
- Matthias Evert
- Elena Wutzlhofer
- Margit Klier-Richter
- Christian Schulz
- Simon Mellin
- Johannes Meier
Institutions
- University Hospital Regensburg (DE)
- Fraunhofer Institute for Toxicology and Experimental Medicine (DE)
- Klinik Bavaria (DE)
- University of Regensburg (DE)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1186/s12916-026-04636-y
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00